



Fiscal Note
H.B. 267

2019 General Session
Prescription Drug Importation Program
by Thurston, N.



General, Education, and Uniform School Funds

JR4-5-101

	Ongoing	One-time	Total
Net GF/EF/USF (rev.-exp.)	\$0	\$(232,500)	\$(232,500)

State Government

UCA 36-12-13(2)(b)

Revenues	FY 2019	FY 2020	FY 2021
Dedicated Credits	\$500,000	\$582,300	\$1,164,800
Total Revenues	\$500,000	\$582,300	\$1,164,800

Enactment of this legislation may result in the Department of Health receiving one-time dedicated credits of \$500,000 in FY 2019 and \$551,600 in FY 2020, and ongoing dedicated credits of \$1,103,300 beginning in FY 2021. Additionally, the Department of Insurance may receive one-time dedicated credits of \$30,700 in FY 2020 and ongoing of \$61,500 beginning in FY 2021.

Expenditures	FY 2019	FY 2020	FY 2021
General Fund, One-Time	\$12,500	\$220,000	\$0
Federal Funds, One-Time	\$37,500	\$780,000	\$0
Dedicated Credits	\$500,000	\$582,300	\$1,164,800
Total Expenditures	\$550,000	\$1,582,300	\$1,164,800

Enactment of this legislation may have one-time implementation costs to the State of \$550,000 in FY 2019 and \$1,582,300 in FY 2020, and ongoing costs, beginning in FY 2021 of \$1,164,800. These costs are from the following funding sources: \$12,500 from the General Fund, \$37,500 from federal funds, and \$500,000 in dedicated credits for FY 2019; \$220,000 from the General Fund, \$780,000 from federal funds, and \$582,300 in dedicated credits FY 2020; and \$1,164,800 in dedicated credits for FY 2021. Additionally, enactment of this legislation may reduce State-funded health insurance pharmacy costs by \$1.5 million and Medicaid pharmacy costs by \$20 million annually beginning in 2020.

	FY 2019	FY 2020	FY 2021
Net All Funds	\$(50,000)	\$(1,000,000)	\$0

Local Government

UCA 36-12-13(2)(c)

Local government-funded health plans may see reduced expenditures in pharmacy drug costs of around \$2.5 million annually beginning in 2020.

Individuals & Businesses

UCA 36-12-13(2)(d)

Privately-funded health insurance plans may see reduced spending on prescription drugs of around \$70 million annually beginning in FY 2020. Additionally, businesses that participate in the prescription drug importation program may pay fees of \$582,300 in FY 2020 and \$1,164,800 annually beginning in FY 2021.

Regulatory Impact

UCA 36-12-13(2)(e)

Enactment of this legislation likely will not change the regulatory burden for Utah residents or businesses.

Performance Note

JR4-2-404

Required of the Health and due by February 08, 2019

Notes on Notes

Fiscal notes estimate the direct costs or revenues of enacting a bill. The Legislature uses them to balance the budget. They do not measure a bill's benefits or non-fiscal impacts like opportunity costs, wait times, or inconvenience. A fiscal note is not an appropriation. The Legislature decides appropriations separately.